These results indicated that ANXA2 expression was closely corelated with the malignant biological process of glioma, and patients with higher levels of ANXA2 expression have a greater risk of tumor recurrence, progression, and therapeutic resistance than other patients. The gene discussed is ANXA2; the disease is glioma.